Optimize IAS
  • Home
  • About Us
  • Courses
    • Prelims Test Series
      • LAQSHYA 2026 Prelims Mentorship
    • Mains Mentorship
      • Arjuna 2026 Mains Mentorship
    • Mains Master Notes
    • PYQ Mastery Program
  • Portal Login
    • Home
    • About Us
    • Courses
      • Prelims Test Series
        • LAQSHYA 2026 Prelims Mentorship
      • Mains Mentorship
        • Arjuna 2026 Mains Mentorship
      • Mains Master Notes
      • PYQ Mastery Program
    • Portal Login

    COMPULSORY LICENSING

    • May 13, 2021
    • Posted by: OptimizeIAS Team
    • Category: DPN Topics
    No Comments

     

     

    COMPULSORY LICENSING

    Subject : Economy

    Context : Kerala High Court seeks Centre’s response to invoke compulsory licensing of Covid vaccines.

    Concept :

    • A compulsory licence is a licence or authorisation issued by the government to an applicant for making, using and selling a patented product or employing a patented process without the consent of the patentee.
    • Chapter XVI of the Indian Patents Act 1970 and the Agreement on Trade-Related Aspects of Intellectual Property Rights discuss compulsory licensing.
    • The application for compulsory license can be made any time after 3 years from date of sealing of a patent.

    The following conditions should be fulfilled by the applicant:

    • Reasonable requirements of the public with respect to the patented invention have not been satisfied;
    • Patented invention is not available to the public at a reasonably affordable price.
    • Patented invention is not used in India.
    • Additionally, according to Section 92 of the Act, compulsory licenses can also be issued suomotu by the Controller of Patents pursuant to a notification issued by the Central Government if there is either a “national emergency” or “extreme urgency” or in cases of “public non-commercial use”.

    When was the first license issued?

    • India’s first ever compulsory license was granted by the Patent Office on March 9, 2012, to Hyderabad-based Natco Pharma for the production of generic version of Bayer’s Nexavar, an anti-cancer agent used in the treatment of liver and kidney cancer.
    COMPULSORY LICENSING economy
    Footer logo
    Copyright © 2015 MasterStudy Theme by Stylemix Themes
        Search